Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications.
Victor L
VL
Serebruany
D001792:Blood Platelets / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D015994:Incidence; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D012307:Risk Factors; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*; D014481:United States / Q000453:epidemiology
D010879:Piperazines; D058919:Purinergic P2 Receptor Antagonists; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride